EUVIMEDEUVIMED entdecken
EditorialKommentar

Sacubitril/Valsartan as an Effective Hypertension Treatment Option in Those With Chronic Type B Aortic Dissection

Michael G Buhnerkempe iD, Stephanie Bitner, John M Flack

American Journal of Hypertension · 2024

DOI: 10.1093/ajh/hpae054 ↗

Kurz gefasst

Editorial in der Zeitschrift American Journal of Hypertension, 2024. Verfasst von Michael G Buhnerkempe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, Illinois, USA. Hauptthemen laut MEDLINE: Valsartan, Aminobutyrates, Biphenyl Compounds, Aortic Dissection. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aortic dissection (AD) impacts around 4.8 per 100,000 individuals per year.1 Intimal tears in the descending aorta, Stanford type B aortic dissections (TBAD), account for 25%–40% of ADs and are associated with relatively high 30-day mortality rates of around 10%.2,3 However, in those that survive the acute phase of TBAD, 3-year mortality rates for chronic TBAD may be as high as 25%, which is higher than that for type A AD and potentially other high-consequence diseases like coronary artery disease, chronic obstructive pulmonary disorder, and stage II colon cancer.4 As such, management of chronic TBAD is vital to improve patient outcomes. However, scientific evidence, and especially clinical trials, to guide clinical decision-making in this area remains relatively scant.3,5 Hypertension is a key modifiable risk factor for AD.6 As such, the overarching goal for medical management of uncomplicated chronic TBAD is to reduce blood pressure (BP) in order to reduce stress on and dilation of the arterial walls.3 The American Heart Association recommends maintenance of systolic BP (SBP)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanAminobutyratesBiphenyl CompoundsAortic DissectionDrug CombinationsHypertensionHumansMaleTreatment OutcomeMiddle AgedChronic DiseaseAntihypertensive AgentsFemaleAgedAngiotensin Receptor AntagonistsTetrazolesBlood PressureAortic AneurysmAngiotensin II Type 1 Receptor Blockers

Substanzen

ValsartanAminobutyratessacubitril and valsartan sodium hydrate drug combinationBiphenyl CompoundsDrug CombinationsAntihypertensive AgentsAngiotensin Receptor AntagonistsTetrazolesAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
  • Center for Clinical Research, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
  • Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, Illinois, USA.

ORCID-Profile: Michael G Buhnerkempe

Zitieren

APA

Buhnerkempe, M. G., Bitner, S., & Flack, J. M. (2024). Sacubitril/Valsartan as an Effective Hypertension Treatment Option in Those With Chronic Type B Aortic Dissection. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae054

Vancouver

Buhnerkempe MG, Bitner S, Flack JM. Sacubitril/Valsartan as an Effective Hypertension Treatment Option in Those With Chronic Type B Aortic Dissection. American Journal of Hypertension. 2024. doi:10.1093/ajh/hpae054

BibTeX
@article{Buhnerkempe2024,
  author = {Buhnerkempe, Michael G and Bitner, Stephanie and Flack, John M},
  title = {Sacubitril/Valsartan as an Effective Hypertension Treatment Option in Those With Chronic Type B Aortic Dissection},
  journal = {American Journal of Hypertension},
  year = {2024},
  doi = {10.1093/ajh/hpae054}
}
Kostenlos starten →